Apintyx Inc. will develop its lead compound, NYX-2925, to treat neuropathic pain linked to diabetic peripheral neuropathy. Read More »

Elusys Therapeutics has published data from five clinical trials of ANTHIM, which was used to support the marketing approval by the U.S. Food and Drug Administration.  Read More »

Corvus Pharmaceuticals presented preclinical data from its Phase1/1b study of CPI-444, and preliminary biomarker data from the trial.  Read More »

Vical Inc. and Astellas Pharma's Phase 2 study of cytomegalovirus vaccine ASP0113 has achieved topline results. Read More »

Diffusion Pharmaceuticals has completed the dosing of two animal toxicology studies that are required by the U.S. Food and Drug Administration for approval of Diffusion’s lead molecule trans sodium crocetinate Phase 3 trial. Read More »

The U.S. Food and Drug Administration has approved Bayer's progestin-containing intrauternine system Kyleena for pregnancy prevention for a span of up to five years. Read More »

Epizyme Inc. has agreed to a partnership with Foundation Medicine to identify and enroll support patients for the upcoming Phase 2 trial of tazemetostat on patients who have non-Hodgkin lymphoma. Read More »

Pacira Pharmaceuticals has released new data supporting EXPAREL and the benefits it could offer patients who must undergo third molar, or wisdom teeth, removal. Read More »

Mucodel Pharma, a private company based in Greensboro, North Carolina, that is dedicated to the development of improved rescue therapies to be administered oromucosally, has completed its Exonal (buccal naloxone) clinical study. Read More »

The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »

Ajanta Pharma USA has made Omeprazole and Sodium Bicarbonate Powder for Oral Suspension available in the United States. Read More »

H. Lundbeck and Otsuka Pharmaceutical Development & Commercialization have reported that the U.S. Food and Drug Administration has approved the update to the Rexulti label. Read More »

Corvus Pharmaceuticals has released the preclinical data and preclinical biomarker data from its Phase 1/1b CPI-444 clinical study. Read More »

AcelRx Pharmaceuticals has commenced with its IAP312 Phase 3 trial for the study of Zalviso, its new investigational product in development to treat moderate-to-severe acute pain in adult hospital patients. Read More »

The U.S. Food and Drug Administration, under a Special Protocol Assessment, has agreed to Athersys' design and analysis of a Multistem Phase 3 study. Read More »

The U.S. Food and Drug Administration has given its approval of the MiniMed 670G hybrid closed looped system, designed to automatically monitor glucose and give suitable dose to individuals 14 years of age and older. Read More »

Eleventa, a portfolio company owned by Maxwell Biotech Venture Fund in association with its development partner Oxagen Ltd., has finalized patient enrollment for its Phase 3 Timapiprant clinical trial. Read More »

Bayer and DelSiTech have issued a joint announcement regarding the signing of a Collaboration and Technology License Agreement. Read More »

Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »

Teva Pharmaceutical Industries has launched Abacavir and Iamivudine tablets, the company’s generic version of Epzicom tablets, in the United States. Read More »